New medicines should have to outperform existing treatments before approval

Debate continues over whether new medicines have to outperform existing treatments befo....

The psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itself

552c7ae14Claim

Competent adults should be allowed to sell a kidney

552c7ae14Claim

A placebo's psychological effect is driven by the patient's confidence in the medical professional and their belief that they are receiving a cure

552c7ae14Claim

Prescribing undisclosed placebos is a form of deception

552c7ae14Claim

Publicly funded healthcare should cover infertility treatment

552c7ae14Claim

Creating human embryos solely for experimentation should be permitted

552c7ae14Claim

Medicare for All is a viable solution to the U.S. healthcare crisis

552c7ae14Claim

The metabolic health benefits of GLP-1 drugs outweigh their dermatological side effects

552c7ae14Claim

The FDA drug recall system catches contamination issues before they reach patients

552c7ae14Claim

Pharmaceutical manufacturing quality standards are sufficient to prevent particulate contamination

552c7ae14Claim

The FDA also announced multiple food recalls in October 2026 including Listeria-contaminated smoked salmon and Salmonella-contaminated broccoli seeds.

552c7ae14Claim

The recall was conducted with the knowledge of the U.S. Food and Drug Administration.

552c7ae14Claim

Argatroban is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia and as an anticoagulant in percutaneous coronary intervention.

552c7ae14Claim

To date, Par Health has not received any reports of adverse events related to this recall.

552c7ae14Claim

Administration of Argatroban Injection containing particulate matter could cause life-threatening adverse health consequences including pulmonary emboli, blood vessel occlusions, and vein inflammation leading to clotting.

552c7ae14Claim

Par Health USA recalled 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) due to the presence of particulate matter including cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel.

552c7ae14Claim

The recall is being conducted to the hospital and user level, with Par Health arranging for return of all existing inventory through Inmar, Inc.

552c7ae14Claim

New medicines should have to outperform existing treatments before approval

Younger patients should receive priority when lifesaving treatment is scarce

Doctors should be allowed to prescribe undisclosed placebos when no effective treatment exists

The psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itself

Competent adults should be allowed to sell a kidney

A placebo's psychological effect is driven by the patient's confidence in the medical professional and their belief that they are receiving a cure

Prescribing undisclosed placebos is a form of deception

Publicly funded healthcare should cover infertility treatment

Creating human embryos solely for experimentation should be permitted

Medicare for All is a viable solution to the U.S. healthcare crisis

The metabolic health benefits of GLP-1 drugs outweigh their dermatological side effects

The FDA drug recall system catches contamination issues before they reach patients

Pharmaceutical manufacturing quality standards are sufficient to prevent particulate contamination

The FDA also announced multiple food recalls in October 2026 including Listeria-contaminated smoked salmon and Salmonella-contaminated broccoli seeds.

The recall was conducted with the knowledge of the U.S. Food and Drug Administration.

Argatroban is a direct thrombin inhibitor indicated for prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia and as an anticoagulant in percutaneous coronary intervention.

To date, Par Health has not received any reports of adverse events related to this recall.

Administration of Argatroban Injection containing particulate matter could cause life-threatening adverse health consequences including pulmonary emboli, blood vessel occlusions, and vein inflammation leading to clotting.

Par Health USA recalled 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) due to the presence of particulate matter including cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel.

The recall is being conducted to the hospital and user level, with Par Health arranging for return of all existing inventory through Inmar, Inc.

The affected lots were distributed nationwide to wholesalers and hospitals between December 30, 2024, and May 5, 2026.